The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical study on the combination of topotecan (TPT) and DDP in the patients with small cell lung cancer
Author(s): 
Pages: 20-21
Year: Issue:  5
Journal: HEILONGJIANG MEDICINE AND PHARMACY

Keyword:  拓扑替康联合顺铂小细胞肺癌疗效安全性;
Abstract: 目的: 探讨盐酸拓扑替康联合顺铂治疗小细胞肺癌[SCLC]的临床疗效和毒性.方法: 初治和复治的小细胞肺癌34例.盐酸拓扑替康0.75mg*[m2]-1*d-1,第1~5天,每次静脉滴注30min;顺铂 30mg*[m2]-1*d-1,第1~3天, 静脉滴注.4周为一周期,共2个周期.结果: 在可评价疗效的34例中,完全缓解[CR]3例,部分缓解[PR]19例有效率[RR]64.70%.初治28例,CR 3例, PR16例,RR为67.85%.复治6例,CR 1例, PR2例,RR为50.00%.局限期29例,CR 4例,PR 16例,RR 68.96%.广泛期5例,CR 0例,PR 2例,RR 40.00%.初治RR高于复治RR,P<0.01;局限期RR高于广泛期RR,P<0.01.大部分患者的症状明显改善.主要的毒副作用是骨髓抑制.结论: 盐酸拓扑替康联合顺铂是治疗小细胞肺癌的有效方案,其毒性反应可以耐受,尤其适宜于复发和耐药的小细胞肺癌.
Related Articles
No related articles found